A case study reviews the reformulation and scale up of high drug load prototype using wet granulation process for a model formulation. The reformulation of a 100-mg tablet into a 300-mgtablet ...
Credit: Genentech. The tablet formulation can either be swallowed whole or dispersed in a teaspoon of filtered (non-chlorinated) water. Each Evrysdi tablet contains 5mg of risdiplam and is suitable ...
This paper reviews considerations for the formulation of chewable tablets including sensory characteristics, chewability assessment, and drug release. Chewable tablets are a versatile dosage form ...
In the pursuit of optimizing tablet performance, CD Formulation, a leading provider of pharmaceutical analysis services, has unveiled a groundbreaking powder flowability testing method. This ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of LIVMARLI ® ...
The approval was based on data from the phase 1 ELEVATE-PLUS trials, which showed the acalabrutinib 100mg tablets were bioequivalent to the acalabrutinib 100mg capsules. The Food and Drug ...
The European Medicines Agency’s human medicines committee has recommended approval of a new tablet formulation of BeOne Medicines’ targeted blood cancer drug Brukinsa (zanubrutinib). The company ...
The trial conducted by the British researchers enrolled 30 participants who were previously unvaccinated and 12 participants who had previously received a standard two-dose vaccine course by injection ...
Pharmaceutical testing is a must to ensure that all medications meet the top quality, safety, and performance requirements before they enter the market. CD Formulation’s cGMP-compliant laboratory is ...
The US Food and Drug Administration (FDA) has granted approval to a tablet formulation of BeOne Medicines’ targeted cancer drug Brukinsa (zanubrutinib). The company formerly known as BeiGene announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results